Early Changes in Waivered Clinicians and Utilization of Buprenorphine for Opioid Use Disorder After Implementation of the 2021 HHS Buprenorphine Practice Guidelines
Link
Description
Report examines the changes in access to buprenorphine
following the implementation of new U.S. Department of
Health and Human Services guidelines as of April 2021.
Discusses the revised guidelines and analyzes their effect
on access to buprenorphine for patients with opioid use
disorder.
Date
12/2022
Organization
U.S. Department of Health and Human Services
Tagged as
Access
· Illicit drug use
· Policy
· Prescription drug misuse
· Statistics and data
· Wellness, health promotion, and disease prevention